MX375701B - Ensayos para igfbp7 con mejor rendimiento en muestras biológicas. - Google Patents

Ensayos para igfbp7 con mejor rendimiento en muestras biológicas.

Info

Publication number
MX375701B
MX375701B MX2016005834A MX2016005834A MX375701B MX 375701 B MX375701 B MX 375701B MX 2016005834 A MX2016005834 A MX 2016005834A MX 2016005834 A MX2016005834 A MX 2016005834A MX 375701 B MX375701 B MX 375701B
Authority
MX
Mexico
Prior art keywords
igfbp7
assays
biological samples
best performance
performance
Prior art date
Application number
MX2016005834A
Other languages
English (en)
Other versions
MX2016005834A (es
Inventor
Ravi A Vijayendran
Srivatsa Venkatasubbarao
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Publication of MX2016005834A publication Critical patent/MX2016005834A/es
Publication of MX375701B publication Critical patent/MX375701B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

La presente invención se refiere a inmunoensayos de IGFBP7 con un mejor rendimiento clínico, particularmente cuando se usan en la evaluación de lesiones renales. Los inmunoensayos dependen en la selección y uso de anticuerpos y pares de anticuerpos que demuestran un mejor rendimiento en los ensayos cuando se usan en especies clínicas complejas, tales como fluidos biológicos, particularmente cuando se usan en formatos de ensayos rápidos, tales como dispositivos de prueba de flujo lateral.
MX2016005834A 2013-11-06 2014-11-06 Ensayos para igfbp7 con mejor rendimiento en muestras biológicas. MX375701B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361900942P 2013-11-06 2013-11-06
US201462054324P 2014-09-23 2014-09-23
US201462064380P 2014-10-15 2014-10-15
PCT/US2014/064327 WO2015069880A1 (en) 2013-11-06 2014-11-06 Assays for igfbp7 having improved performance in biological samples

Publications (2)

Publication Number Publication Date
MX2016005834A MX2016005834A (es) 2016-11-17
MX375701B true MX375701B (es) 2025-03-06

Family

ID=53042071

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005834A MX375701B (es) 2013-11-06 2014-11-06 Ensayos para igfbp7 con mejor rendimiento en muestras biológicas.

Country Status (12)

Country Link
US (3) US9822172B2 (es)
EP (2) EP3556863B1 (es)
JP (4) JP2017501211A (es)
KR (1) KR102404285B1 (es)
CN (1) CN105793439B (es)
AU (1) AU2014346695B2 (es)
BR (1) BR112016010106A2 (es)
CA (2) CA2929547C (es)
EA (1) EA201690731A1 (es)
HK (1) HK1221490A1 (es)
MX (1) MX375701B (es)
WO (1) WO2015069880A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009308497B2 (en) 2008-10-21 2014-10-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EA201290387A1 (ru) 2009-12-20 2013-02-28 Астьют Медикал, Инк. Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
NZ605698A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US10935548B2 (en) 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
TR201807542T4 (tr) 2013-01-17 2018-06-21 Astute Medical Inc Böbrek hasarı ve böbrek yetmezliği teşhisi ve prognozuna yönelik metotlar ve bileşimler.
US10300108B2 (en) 2013-12-03 2019-05-28 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BR112017005554A2 (en) * 2014-10-29 2018-01-23 F. Hoffmann-La Roche Ag methods for predicting a subject's risk of rapid progression to chronic heart failure and uses of at least one biomarker and at least one binding agent
EP3281011B1 (en) 2015-04-09 2024-06-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3359966B1 (en) * 2015-10-08 2020-01-01 Roche Diagnostics GmbH Igfbp7 for prediction of risk of aki when measured prior to surgery
US11243217B2 (en) 2016-06-06 2022-02-08 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
WO2018145117A1 (en) 2017-02-06 2018-08-09 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2018187453A1 (en) 2017-04-05 2018-10-11 Astute Medical, Inc. Assays for timp2 having improved performance in biological samples
US11435364B2 (en) 2018-05-24 2022-09-06 Renibus Therapeutics, Inc. Methods of treating patients at risk for renal injury and renal failure
WO2020234482A1 (en) * 2019-05-21 2020-11-26 Universität Zürich MAPKi RESISTANCE SIGNATURES
KR102533791B1 (ko) * 2022-09-15 2023-05-18 경북대학교 산학협력단 비색법 신호형질 복합체, 이를 이용하는 신장질환 진단용 키트 및 진단법

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3029579C2 (de) 1980-08-05 1985-12-12 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren und Mittel zur Abtrennung von Plasma oder Serum aus Vollblut
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
US5166051A (en) 1990-08-08 1992-11-24 Genesis Labs, Inc. Membranes, membrane overlays for exclusion of erythrocytes, and method for immunoassay of whole blood analytes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JPH05504841A (ja) 1990-09-14 1993-07-22 バイオサイト・ダイアグノスティックス・インコーポレイテッド リガンドレセプター及びリガンドのコンプレックスに対する抗体及びリガンド―レセプターアッセーでのそれらの用途
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
EP0585310B1 (en) 1991-04-10 1999-03-17 Biosite Diagnostics Inc. Crosstalk inhibitors and their uses
AU1911592A (en) 1991-04-10 1992-11-17 Biosite Diagnostics Incorporated Novel conjugates and assays for simultaneous detection of multiple ligands
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
KR100654645B1 (ko) 1995-04-27 2007-04-04 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6391265B1 (en) 1996-08-26 2002-05-21 Biosite Diagnostics, Inc. Devices incorporating filters for filtering fluid samples
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
US6045899A (en) 1996-12-12 2000-04-04 Usf Filtration & Separations Group, Inc. Highly assymetric, hydrophilic, microfiltration membranes having large pore diameters
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
US7109030B2 (en) * 2000-03-31 2006-09-19 Nuvelo, Inc. Methods of therapy and diagnosis using insulin-like growth factor binding protein-like polypeptides and polynucleotides
US20020132983A1 (en) 2000-11-30 2002-09-19 Junghans Richard P. Antibodies as chimeric effector cell receptors against tumor antigens
WO2006119203A2 (en) * 2005-04-29 2006-11-09 Beckman Coulter Fluorescence lateral flow immunoassay
BRPI0613387A2 (pt) 2005-07-08 2011-01-11 Biogen Idec Inc anticorpo isolado ou fragmento de ligação de antìgeno deste e o seu uso, polinucleotìdeo isolado, composição, vetor, célula hospedeira, anticorpo anti-sp35 e método para a produção do mesmo, polipeptìdeo isolado, método in vitro para redução da inibição do crescimento axonal e método in vitro para inibição do crescimento do colapso do cone
WO2008089994A1 (en) * 2007-01-25 2008-07-31 Roche Diagnostics Gmbh Use of igfbp-7 in the assessment of heart failure
US9164097B2 (en) * 2008-10-14 2015-10-20 National Research Council Of Canada Formulations targeting IGFBP7 for diagnosis and therapy of cancer
MX2011011670A (es) 2009-05-01 2011-11-18 Abbott Lab Inmunoglobulinas de dominio variable dual y usos de las mismas.
EA201290387A1 (ru) 2009-12-20 2013-02-28 Астьют Медикал, Инк. Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
ES2585184T3 (es) * 2010-02-05 2016-10-04 Astute Medical, Inc. Procedimientos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
US20130224191A1 (en) 2010-08-27 2013-08-29 Robert A. Stull Notum protein modulators and methods of use
AU2012332193A1 (en) * 2011-11-03 2014-05-15 Tolera Therapeutics, Inc. Antibody and methods for selective inhibition of T-cell responses

Also Published As

Publication number Publication date
EP3066221A1 (en) 2016-09-14
EP3556863A1 (en) 2019-10-23
CA3185700A1 (en) 2015-05-14
CA2929547C (en) 2023-02-28
HK1221490A1 (zh) 2017-06-02
CA2929547A1 (en) 2015-05-14
US10562961B2 (en) 2020-02-18
AU2014346695A1 (en) 2016-06-16
US20180066045A1 (en) 2018-03-08
US20200247879A1 (en) 2020-08-06
AU2014346695B2 (en) 2020-10-15
KR20160068988A (ko) 2016-06-15
US20160289308A1 (en) 2016-10-06
JP7277623B2 (ja) 2023-05-19
MX2016005834A (es) 2016-11-17
JP2020048569A (ja) 2020-04-02
CN105793439B (zh) 2020-09-04
JP2022068143A (ja) 2022-05-09
US9822172B2 (en) 2017-11-21
JP2023052239A (ja) 2023-04-11
WO2015069880A1 (en) 2015-05-14
EA201690731A1 (ru) 2016-10-31
JP2017501211A (ja) 2017-01-12
CN105793439A (zh) 2016-07-20
EP3556863B1 (en) 2024-09-18
EP3066221A4 (en) 2017-09-20
BR112016010106A2 (pt) 2017-12-05
KR102404285B1 (ko) 2022-05-31

Similar Documents

Publication Publication Date Title
MX375701B (es) Ensayos para igfbp7 con mejor rendimiento en muestras biológicas.
MX2016001573A (es) Ensayos para timp2 con mejor rendimiento en muestras biológicas.
MX377956B (es) Sistemas y métodos para maximización de uso de muestras.
BR112016019836A2 (pt) método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito
MX2015012823A (es) Ensayo de combinacion de antigeno-anticuerpo del virus de la hepatitis c (vhc) y metodos y composiciones para usarlo.
NI201500103A (es) Anticuerpos cd47 que no agotan plaquetas ni glóbulos rojos y métodos de uso de los mismos.
MX384536B (es) Sistemas y metodos para multiples analisis.
MX2017000116A (es) Moleculas basadas en il-15 y metodos para su uso.
MX374652B (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco.
BR112016003665A2 (pt) anticorpos e ensaios para detecção do receptor 1 de folato
WO2013096822A3 (en) Test device for optical and electrochemical assays
MX2018015704A (es) Control de fluidos.
MX2017014139A (es) Anticuerpos anti-cd71, anticuerpos anti-cd71 activables, y metodos de uso de los mismos.
MX388999B (es) Aparato y métodos de prueba para biomarcador cardiaco st2.
CR20140382A (es) Anticuerpos anti-lrp5 y metodos de uso
WO2014015194A3 (en) Methods for detecting and measuring aggregation
MX377772B (es) Inmunoensayo de canalización de oxígeno luminiscente utilizando tres anticuerpos y metodos de produccion y uso de los mismos.
BR112015007672A2 (pt) anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
BR112015022490A2 (pt) métodos e composições para classificação de amostras
CO6721041A2 (es) Anticuerpo anti-pcsk9 y métodos de uso
BR112013023540A2 (pt) anticorpo, kit e método para a determinação de peptídeos amilóides
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
CO7280144A2 (es) Moléculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc
MX2017009485A (es) Detección y aislamiento de células fetales basadas en microfluidos para prueba prenatal no invasiva.
SA518391028B1 (ar) Cd37 أجسام مضادة واختبارات للكشف عن

Legal Events

Date Code Title Description
FG Grant or registration